MY127181A - Substituted bicyclic derivatives for the treatment of abnormal cell growth - Google Patents

Substituted bicyclic derivatives for the treatment of abnormal cell growth

Info

Publication number
MY127181A
MY127181A MYPI20012895A MY127181A MY 127181 A MY127181 A MY 127181A MY PI20012895 A MYPI20012895 A MY PI20012895A MY 127181 A MY127181 A MY 127181A
Authority
MY
Malaysia
Prior art keywords
cell growth
abnormal cell
treatment
substituted bicyclic
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Morris Joel
Charles Kath John
Kumar Bhattacharya Samit
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MY127181A publication Critical patent/MY127181A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MYPI20012895 2000-06-22 2001-06-20 Substituted bicyclic derivatives for the treatment of abnormal cell growth MY127181A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21313600P 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
MY127181A true MY127181A (en) 2006-11-30

Family

ID=22793862

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20012895 MY127181A (en) 2000-06-22 2001-06-20 Substituted bicyclic derivatives for the treatment of abnormal cell growth

Country Status (42)

Country Link
US (2) US6890924B2 (en, 2012)
EP (1) EP1292591B1 (en, 2012)
JP (1) JP4044839B2 (en, 2012)
KR (1) KR100545537B1 (en, 2012)
CN (3) CN1330640C (en, 2012)
AP (1) AP2001002192A0 (en, 2012)
AR (1) AR032353A1 (en, 2012)
AT (1) ATE288431T1 (en, 2012)
AU (1) AU2001264159A1 (en, 2012)
BG (1) BG107269A (en, 2012)
BR (1) BR0111548A (en, 2012)
CA (1) CA2413424C (en, 2012)
CZ (1) CZ20023951A3 (en, 2012)
DE (1) DE60108754T2 (en, 2012)
DK (1) DK1292591T3 (en, 2012)
DZ (1) DZ3407A1 (en, 2012)
EA (1) EA005525B1 (en, 2012)
EC (1) ECSP024393A (en, 2012)
EE (1) EE200200710A (en, 2012)
ES (1) ES2236240T3 (en, 2012)
GE (1) GEP20063831B (en, 2012)
HR (1) HRP20021005A2 (en, 2012)
HU (1) HUP0301120A2 (en, 2012)
IL (1) IL152985A0 (en, 2012)
IS (1) IS6616A (en, 2012)
MA (1) MA26914A1 (en, 2012)
MX (1) MXPA02012870A (en, 2012)
MY (1) MY127181A (en, 2012)
NO (1) NO20026166L (en, 2012)
NZ (1) NZ522568A (en, 2012)
OA (1) OA12291A (en, 2012)
PA (1) PA8520301A1 (en, 2012)
PE (1) PE20020257A1 (en, 2012)
PL (1) PL359557A1 (en, 2012)
PT (1) PT1292591E (en, 2012)
SK (1) SK17102002A3 (en, 2012)
SV (1) SV2002000504A (en, 2012)
TN (1) TNSN01091A1 (en, 2012)
UA (1) UA73990C2 (en, 2012)
WO (1) WO2001098277A2 (en, 2012)
YU (1) YU95102A (en, 2012)
ZA (1) ZA200210231B (en, 2012)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
PT1117653E (pt) * 1998-10-01 2003-06-30 Astrazeneca Ab Derivados de quinolina e quinazolina e sua utilizacao como inibidores de doencas mediadas pela citosina
CN1330640C (zh) * 2000-06-22 2007-08-08 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
ATE475652T1 (de) * 2001-02-21 2010-08-15 Mitsubishi Tanabe Pharma Corp Chinazolinderivate
US20030144308A1 (en) * 2001-09-24 2003-07-31 Bauer Paul H. Fructose 1,6-bisphosphatase inhibitors
AU2002337428A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
EA007412B1 (ru) * 2001-12-12 2006-10-27 Пфайзер Продактс Инк. Соли е-2-метокси-n-(3-(4-(3-метилпиридин-3-илокси)фениламино)хиназолин-6-ил-аллил)ацетамида, их получение и их применение против рака
EP1465632A1 (en) * 2001-12-12 2004-10-13 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP4703183B2 (ja) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． 受容体型キナーゼモジュレーターおよびその使用方法
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
EP1567506A4 (en) 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
MXPA05006335A (es) * 2002-12-18 2005-08-26 Pfizer Prod Inc Derivados biciclicos para el tratamiento del crecimiento celular anormal.
KR20050085835A (ko) * 2002-12-19 2005-08-29 화이자 프로덕츠 인코포레이티드 Ｅ-2-메톡시-ｎ-（3-｛4-［3-메틸-4-（6-메틸-피리딘-3-일옥시）-페닐아미노］-퀴나졸린-6-일｝-알릴）-아세트아마이드의 착물, 및 그의 제조방법 및 용도
BRPI0409233A (pt) * 2003-04-09 2006-03-28 Pfizer Prod Inc processos para a preparação de derivados de n-((((piridinilóxi)-fenilaminoquinazolinil)-alil) acetamida e compostos relacionados, bem como intermediários de tais processos e processos para a preparação de tais intermediários
JP2007501854A (ja) * 2003-05-27 2007-02-01 ファイザー・プロダクツ・インク 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド［３，４−ｄ］ピリミジン類
KR101218213B1 (ko) * 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
CA2529777A1 (en) * 2003-07-15 2005-01-27 National Research Council Of Canada Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
PL1660090T3 (pl) * 2003-08-14 2013-04-30 Array Biopharma Inc Analogi chinazoliny jako inhibitory kinaz tyrozynowych receptora
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2005016347A1 (en) * 2003-08-18 2005-02-24 Pfizer Products Inc. Dosing schedule for erbb2 anticancer agents
RU2378268C2 (ru) 2003-09-16 2010-01-10 Астразенека Аб Производные хиназолина в качестве ингибиторов тирозинкиназы
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
CA2544863A1 (en) * 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
NZ552091A (en) 2004-07-16 2009-09-25 Pfizer Prod Inc Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
CN101010304A (zh) * 2004-09-01 2007-08-01 三菱制药株式会社 分子伴侣功能调节剂
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
KR100990027B1 (ko) 2005-04-26 2010-10-26 화이자 인코포레이티드 Ｐ-카드헤린 항체
CA2610491A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Bicyclic derivatives for the treatment of abnormal cell growth
EP1896030A1 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
PT1933871E (pt) 2005-09-07 2013-07-17 Pfizer Anticorpos monoclonais humanos para cinase-1 do tipo receptor de activina
JP5134548B2 (ja) * 2005-11-15 2013-01-30 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
BRPI0711358A2 (pt) 2006-05-09 2011-09-27 Pfizer Prod Inc derivados do ácido cicloalquilamino e suas composições farmacêuticas
WO2008002039A1 (en) * 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US8604044B2 (en) * 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
KR20090090336A (ko) 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
JP5336516B2 (ja) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
AR070874A1 (es) 2008-03-12 2010-05-12 Takeda Pharmaceutical Compuesto heterociclico fusionado, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer.
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
KR20230008268A (ko) 2009-01-16 2023-01-13 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
WO2012052948A1 (en) 2010-10-20 2012-04-26 Pfizer Inc. Pyridine- 2- derivatives as smoothened receptor modulators
WO2013042006A1 (en) 2011-09-22 2013-03-28 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
CN102872018B (zh) * 2012-10-23 2015-07-15 广州市恒诺康医药科技有限公司 酪氨酸激酶不可逆抑制剂及其制备方法和用途
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
US20170050958A1 (en) 2014-04-30 2017-02-23 Pfizer Inc. Cycloalkyl-Linked Diheterocycle Derivatives
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
CN107922609B (zh) 2015-07-01 2020-04-24 加州理工学院 基于阳离子粘酸聚合物的递送系统
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10828305B2 (en) 2016-03-01 2020-11-10 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
CA3099776A1 (en) 2018-09-18 2020-03-26 Suzhou Zanrong Pharma Limited Quinazoline derivatives as antitumor agents
JP2025509995A (ja) * 2022-03-28 2025-04-11 江蘇恒瑞医薬股▲ふん▼有限公司 含窒素複素環系化合物、その調製方法及びその医薬的使用
WO2025067396A1 (zh) * 2023-09-27 2025-04-03 江苏恒瑞医药股份有限公司 一种喹唑啉衍生物的可药用盐、其结晶形式及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (en, 2012) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
KR100860295B1 (ko) 1998-10-08 2008-09-25 아스트라제네카 아베 퀴나졸린 유도체
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CN1330640C (zh) * 2000-06-22 2007-08-08 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物

Also Published As

Publication number Publication date
YU95102A (sh) 2005-11-28
CZ20023951A3 (cs) 2004-01-14
ZA200210231B (en) 2004-02-12
PT1292591E (pt) 2005-06-30
SV2002000504A (es) 2002-10-24
SK17102002A3 (sk) 2004-04-06
BG107269A (bg) 2003-06-30
PL359557A1 (en) 2004-08-23
ES2236240T3 (es) 2005-07-16
EP1292591B1 (en) 2005-02-02
US6890924B2 (en) 2005-05-10
HK1069576A1 (en) 2005-05-27
WO2001098277A2 (en) 2001-12-27
EA200201277A1 (ru) 2003-06-26
CN1437594A (zh) 2003-08-20
JP2004501139A (ja) 2004-01-15
GEP20063831B (en) 2006-05-25
CN1330640C (zh) 2007-08-08
NO20026166D0 (no) 2002-12-20
AR032353A1 (es) 2003-11-05
CA2413424A1 (en) 2001-12-27
DZ3407A1 (en, 2012) 2001-12-27
DE60108754D1 (de) 2005-03-10
CN101348467A (zh) 2009-01-21
UA73990C2 (en) 2005-10-17
HUP0301120A2 (hu) 2003-08-28
MA26914A1 (fr) 2004-12-20
NZ522568A (en) 2004-12-24
ATE288431T1 (de) 2005-02-15
IL152985A0 (en) 2003-06-24
NO20026166L (no) 2002-12-20
US20050159435A1 (en) 2005-07-21
KR100545537B1 (ko) 2006-01-25
DE60108754T2 (de) 2005-06-23
CN1576275A (zh) 2005-02-09
HRP20021005A2 (en) 2004-02-29
CA2413424C (en) 2007-10-02
WO2001098277A3 (en) 2002-06-13
BR0111548A (pt) 2003-05-06
OA12291A (en) 2004-03-18
US20020169165A1 (en) 2002-11-14
JP4044839B2 (ja) 2008-02-06
EE200200710A (et) 2004-06-15
PA8520301A1 (es) 2003-06-30
MXPA02012870A (es) 2003-05-14
US7332493B2 (en) 2008-02-19
ECSP024393A (es) 2003-02-06
EP1292591A2 (en) 2003-03-19
AP2001002192A0 (en) 2002-12-21
EA005525B1 (ru) 2005-04-28
TNSN01091A1 (fr) 2005-11-10
KR20030016303A (ko) 2003-02-26
DK1292591T3 (da) 2005-05-30
AU2001264159A1 (en) 2002-01-02
IS6616A (is) 2002-11-14
PE20020257A1 (es) 2002-04-08

Similar Documents

Publication Publication Date Title
MY127181A (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
RS20050180A (en) Novel benzoimidazole derivatives useful as antiproliferative agensts
ATE260263T1 (de) Heteroaromatische bizyklische verbindungen mit antikrebswirkung
DE69923849D1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
BG104998A (en) Isothiazole derivatives useful as anticancer agents
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
AP2001002079A0 (en) Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents.
MX9707980A (es) Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos.
MY136270A (en) Processes and intermediates for preparing anti-cancer compounds
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
TNSN02096A1 (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
WO2006129168A3 (en) Bicyclic derivatives for the treatment of abnormal cell growth
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
MXPA02011966A (es) Derivados de higromicina a para el el tratamiento de infecciones bacterianas y por protozoarios.
UY26785A1 (es) Derivados bicíclicos sustituidos para el tratamiento del crecimiento celular anormal